This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-generation innovations are helping…
The plan builds on recent FDA moves to speed “personalized” treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease. The promise of personalized gene-editing therapies burst into the national conversation in May…
A new protocol details PINE-TREE, a transient fluorescent reporter system that enriches prime-edited human pluripotent stem cells and yields up to 80 percent editing efficiency in sorted populations.
A new closed-tube RT-RAA-CRISPR/Cas12a assay detects Schmallenberg virus within 50 minutes and outperformed RT-qPCR on simulated bovine nasal swab samples, though validation with authentic clinical specimens is still pending. Subject of Research: Development of a rapid visual RT-RAA-CRISPR/Cas12a nucleic acid assay…
Researchers generated the first two CRISPR chd2-knockout zebrafish strains and found that a four-base deletion and a one-base deletion in the same gene produced opposite effects on embryo mortality, deformity and larval excitability. Article Title: Effects of two chd2-knockout strains…
Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA to proteins. But only two percent of the human genome actually encodes proteins; the function of the remaining 98 percent…
What doesn’t kill a bacterium makes it stronger. An enzyme that bacteria use to fight off viruses works by targeting not just the virus, but also the bacterium itself. It sends the bacterium into a dormant state and makes it…
A new review highlights the potential of CRISPR–Cas13 for RNA-editing therapies. Discussing the advantages of the effector protein Cas13 over Cas9, they report that CRISPR–Cas13 facilitates RNA knockdown, RNA silencing, RNA splicing, RNA-base editing, and translation regulation. CRISPR–Cas13 has diverse applications like…
A new review argues that CRISPR antivirals, especially RNA-targeting Cas13 systems, can suppress respiratory viruses in preclinical models, with lung delivery, safety, and regulation now the main barriers to clinical use. News Source: Juliet Wilcox. (October 29, 2026). CRISPR Antivirals Target Respiratory Viruses,…
A long-running debate over how an important gene-silencing protein identifies its targets has been resolved by researchers at Massachusetts General Hospital (MGH). Their findings, reported in Nature Structural and Molecular Biology, also explain certain mysteries about the behavior of this…
CRISPR and the gene editors built on it: new editing tools, editing therapies given to patients, and gene drives for wild populations.
An article joins this feed when it matches these terms. Each one is also a search of its own.